In a subsequent animal model-based mechanistic study administering recombinant CXCL13 to mice with lung cancer, it was demonstrated that CXCL13 treatment enhanced therapeutic PD-1 blockade by increasing antigen-experienced T cell subsets (135). The gene discussed is CXCL13; the disease is lung cancer.